Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coherus Oncology, Inc.CHRS · Entity 6276 | Director | June 05, 2026 | June 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coherus Oncology, Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,000 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 30,000 · Balance 30,000 F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2036-06-05 | Direct | 60,000 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Grant · Acquired 60,000 · Balance 60,000 F2: The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.
F2: The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 9, 2026 22:41 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001610717-26-000203 · form4.xml · derivative · entry 2 Ryan Michael Lee · CIK 0001985918 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-06-05 F2 · derivative.exercise_date: The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 22:41 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000203 · form4.xml · nonDerivative · entry 1 Ryan Michael Lee · CIK 0001985918 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 22:49 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 112,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001610717-25-000226 · form4.xml · derivative · entry 1 Ryan Michael Lee · CIK 0001985918 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 112,000 shares Expires 2035-06-12 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the one year anniversary of June 11, 2025, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 22:51 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 112,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001610717-24-000291 · form4.xml · derivative · entry 1 Ryan Michael Lee · CIK 0001985918 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 112,000 shares Expires 2034-06-03 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the one year anniversary of June 3, 2024, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 21:11 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 54,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001610717-23-000207 · form4.xml · derivative · entry 1 Ryan Michael Lee · CIK 0001985918 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2033-07-18 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/36th of the total number of shares subject to the option in successive, equal monthly installments measured from July 18, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.